Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022

• Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, as monotherapy or in combination with durvalumab, in advanced solid tumors to be presented by partner AstraZeneca 

• Preclinical data supporting rationale for the Phase 2 development of IPH5201 in non-small cell lung cancer will be presented 

• Trial in Progress poster for IPH5301, a CD73-blocking monoclonal antibody investigated in collaboration with the Institut Paoli-Calmettes, will also be presented by the IPC

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland.

The following posters will be presented:

IPH5201 as monotherapy or in combination with durvalumab in advanced solid tumors (AstraZeneca)

• Abstract Number: 472 
• Session Name: Poster Display 188P
• Session Time: 8 December, 12:30-13:15
• Location: Palexpo exhibition centre – Foyer ABC
• Presenter: Dr. Martina Imbimbo, Head of Clinic for the Immuno-oncology Department within the Department of Oncology at UNIL CHUV (Lausanne, Switzerland)

Combination of IPH5201, a block antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale

• Abstract Number: 384 
• Session Name: Poster Display 190P
• Session Time: 8 December, 12:30-13:15
• Location: Palexpo exhibition centre – Foyer ABC
• Presenter: Carine Paturel, Senior Director, Research and Drug Development, Products Portfolio Strategy, Innate Pharma (Marseille, France) 

A first-in-human phase I study of IPH5301, an anti-CD73 monoclonal antibody, alone or in combination with chemotherapy and trastuzumab, in patients with advanced solid tumors (CHANCES) (Institut Paoli-Calmettes)

• Abstract Number: 290 
• Session Name: Poster Display 199TiP
• Session Time: 8 December, 12:30-13:15
• Location: Palexpo exhibition centre – Foyer ABC
• Presenter: Dr. Anthony Gonçalves, Professor of Medical Oncology, Institut Paoli-Calmettes (Marseille, France)

The posters will be available on the Publications section of Innate’s website following the meeting.

About IPH5201

IPH5201 is a CD39-blocking monoclonal antibody that may promote antitumor immunity by increasing immunostimulatory ATP and reducing immunosuppressive adenosine levels in the tumor microenvironment. It is being developed in partnership with AstraZeneca.
A first-in-human, multi-centre, non-randomised, open-label, phase 1 study (NCT04261075) sponsored by AstraZeneca assessed the safety, efficacy, pharmacokinetics and pharmacodynamics of IPH5201 as monotherapy and in combination with durvalumab in patients with advanced solid tumors.
A Phase 2 clinical trial conducted by Innate in lung cancer is in planning.

About IPH5301

IPH5301 is a CD73-blocking monoclonal antibody currently in an investigator-sponsored Phase 1 trial in collaboration with the Institut Paoli-Calmettes (IPC) and Oncodistinct Network.
By targeting the adenosine immunosuppressive pathway, IPH5301 has the potential to promote anti-tumor immune responses across a wide range of tumors.